[
  {
    "question": "A 26-year-old female with AIDS (CD4 count: 47) presents to the emergency department in severe pain. She states that over the past week she has been fatigued and has had a progressively worse headache and fever. These symptoms have failed to remit leading her to seek care in the ED. A lumbar puncture is performed which demonstrates an opening pressure of 285 mm H2O, increased lymphocytes, elevated protein, and decreased glucose. The emergency physician subsequently initiates treatment with IV amphotericin B and PO flucytosine. What additional treatment in the acute setting may be warranted in this patient?",
    "answer": "A. Hydrocortisone\nB. Indomethacin\nC. Corticosteroids\nD. Corticosteroids and hydrocortisone\nAnswer: C\nExplanation: The patient in this vignette has Cryptococcal meningitis. In the acute setting, the use of corticosteroids is recommended in patients with increased intracranial pressure. The Infectious Diseases Society of America recommends the use of corticosteroids in patients with increased intracranial pressure. \nThe best answer is C.",
    "true_answer": "In the acute setting, serial lumbar punctures may be warranted for this patient to manage elevated intracranial pressure."
  },
  {
    "question": "You are reviewing raw data from a research study performed at your medical center examining the effectiveness of a novel AIDS screening examination. The study enrolled 250 patients with confirmed AIDS, and 240 of these patients demonstrated a positive screening examination. The control arm of the study enrolled 250 patients who do not have AIDS, and only 5 of these patients tested positive on the novel screening examination. What is the NPV of this novel test?",
    "answer": "_\n_Solution: To calculate the NPV of the test, you need to know the total number of patients who do not have AIDS (250) and the number of these patients who tested negative (245). The NPV is the ratio of true negatives (245) to the sum of true negatives (245) and false negatives (10), or 245/(245 + 10) = 96%._\n\\[\\text{NPV}=\\frac{\\text{TN}}{\\text{TN}+\\text{FN}}\\]\n_Answer: The NPV of this test is 96%._\nThe PPV and NPV are influenced by the prevalence of disease in the population being tested. The higher the prevalence of disease, the higher the PPV and the lower the NPV. Conversely, the lower the prevalence of disease, the lower the PPV and the higher the NPV.\n\\[\\text{PPV}=\\frac{(\\text{Sensitivity})(\\text{Prevalence})}{(\\text{Sensitivity})( \\text{Prevalence})+(1-\\text{Specificity})(1-\\text{Prevalence})}\\]\n\\[\\text{NPV}=\\frac{(\\text{Specificity})(1-\\text{Prevalence})}{(1-\\text{Sensitivity})( \\text{Prevalence})+(\\text{Specificity})(1-\\text{Prevalence})}\\]\nIn addition to the sensitivity, specificity, PPV, and NPV, there are several other statistical terms that are used to describe the results of a diagnostic test.\n* **Accuracy** refers to the test's ability to correctly diagnose a condition, and is the sum of true positives and true negatives divided by the total number of patients tested.\n* **Likelihood ratio (LR)** is the ratio of the probability of a test result among patients with disease to the probability of the same test result among patients without disease. A LR of 1 implies that the test result is equally likely to occur in patients with and without disease. A LR > 1 increases the likelihood that disease is present, while a LR < 1 decreases the likelihood of disease.\n* **Receiver operating characteristic (ROC) curve** is a graphical representation of the trade-off between sensitivity and specificity of a test. The area under the ROC curve (AUC) is a measure of the test's accuracy, with an AUC of 1.0 being a perfect test and an AUC of 0.5 being no better than chance.\n* **Number needed to diagnose (NND)** is the number of patients who need to be tested to diagnose one patient with disease. It is the inverse of the PPV.\n* **Number needed to misdiagnose (NNM)** is the number of patients who need to be tested to misdiagnose one patient with disease. It is the inverse of (1-specificity).\n* **Bayes' theorem** is used to update the probability of disease based on the results of a diagnostic test. It incorporates the pretest probability of disease, the sensitivity and specificity of the test, and the test result to calculate a posttest probability of disease.\n_Example 2: A 35-year-old woman undergoes a screening mammogram, which shows a suspicious mass. The mammogram has a sensitivity of 90% and a specificity of 95%. The prevalence of breast cancer in this age group is 0.1%. What is the probability that this woman has breast cancer given a positive mammogram?_\n_Solution: Using Bayes' theorem, we can calculate the posttest probability of breast cancer given a positive mammogram._\n\\[\\text{Posttest probability}=\\frac{(\\text{Pretest probability})(\\text{Sensitivity})}{(\\text{Pretest probability})(\\text{Sensitivity})+(1-\\text{Pretest probability})(1-\\text{Specificity})}\\]\n\\[\\text{Posttest probability}=\\frac{(0.001)(0.9)}{(0.001)(0.9)+(1-0.001)(1-0.95)}\\]\n\\[\\text{Posttest probability}=\\frac{0.0009}{0.0009+0.0495}\\]\n\\[\\text{Posttest probability}=0.018\\]\n_Answer: The probability that this woman has breast cancer given a positive mammogram is 1.8%._The use of Bayes' theorem allows clinicians to incorporate the results of a diagnostic test into their decision-making process, and to update the probability of disease based on the test results. This can help to reduce unnecessary testing and treatment, and to improve patient outcomes.\n_Example 3: A 60-year-old man presents to his primary care physician with symptoms of cough and shortness of breath. The physician orders a chest X-ray, which shows a mass in the right lung. The physician suspects lung cancer, and orders a CT scan of the chest. The CT scan has a",
    "true_answer": "The NPV of this test is calculated as the proportion of true negatives among all negative results, 245 / (245 + 10) = 0.96."
  },
  {
    "question": "A 46-year-old Caucasian male with past medical history of HIV (CD4: 77/mm^3), hypertension, hyperlipidemia, and osteoarthritis presents to the emergency department with sudden weakness of his right hand. He reports that the weakness has gradually been getting worse and that this morning he dropped his cup of coffee. He has never had anything like this happen to him before, although he was hospitalized last year for pneumonia. He reports inconsistent adherence to his home medications, which include raltegravir, tenofovir, emtricitabine, TMP-SMX, hydrochlorothiazide, pravastatin, and occasional ibuprofen. His father died of a myocardial infarction at the age of 60, and his mother suffered a stroke at the age of 72. The patient's temperature is 102.6\u00b0F (39.2\u00b0C), blood pressure is 156/92 mmHg, pulse is 88/min, and respirations are 18/min. On neurological exam, he has 3/5 strength in the distal muscles of the right extremity with preserved sensation. His neurological exam is normal in all other extremities. What is the next best step in management for this patient?",
    "answer": "The patient's presentation with sudden weakness of one hand, fever, and a history of HIV with a low CD4 count, suggests an infectious or inflammatory cause, such as an opportunistic infection affecting the central nervous system (CNS) or a peripheral nerve issue. Given the patient's immunocompromised state, it is crucial to consider CNS opportunistic infections such as toxoplasmosis, cryptococcal meningitis, or progressive multifocal leukoencephalopathy (PML), among others. The presence of fever and focal neurological deficits (weakness in one hand) necessitates immediate imaging and further diagnostic workup to identify the cause.\n\nThe next best steps in management would include:\n\n1. **Imaging Studies**: A stat MRI of the brain with and without contrast is essential to evaluate for any focal lesions, masses, or signs of infection that could explain the patient's symptoms. This would help differentiate between various CNS opportunistic infections, strokes, or other pathologies.\n\n2. **Laboratory Tests**: \n   - **Complete Blood Count (CBC)**: To assess for signs of infection or inflammation.\n   - **Blood Cultures**: To identify any systemic infection.\n   - **HIV Viral Load**: To assess the current level of viral suppression.\n   - **CD4 Count**: Already provided, but monitoring is essential.\n   - **Cerebrospinal Fluid (CSF) Analysis**: Lumbar puncture (LP) for CSF examination, including cell count, glucose, protein, and appropriate cultures and PCR tests for opportunistic pathogens (e.g., toxoplasmosis, cryptococcus, JC virus for PML), would be crucial. However, LP should ideally be performed after imaging to rule out space-occupying lesions that could lead to herniation.\n\n3. **Empiric Treatment**: Based on the suspicion of an opportunistic CNS infection, empiric treatment may be started while awaiting diagnostic results. For example, if toxoplasmosis is suspected, sulfadiazine and pyrimethamine could be initiated. If cryptococcal meningitis is a concern, amphotericin B and flucytosine may be started. Empiric antibiotic coverage for bacterial meningitis might also be considered, especially given the patient's fever and immunocompromised state.\n\n4. **Neurological Consultation**: Consulting with a neurologist, preferably one with experience in HIV-related neurological disorders, would be beneficial for further guidance on diagnosis and management.\n\n5. **Adherence to Antiretroviral Therapy (ART)**: Ensuring the patient is adherent to his ART regimen is crucial to improve his immune status, which can help in managing or preventing opportunistic infections.\n\n6. **Supportive Care**: Managing the patient's fever, pain, and any other symptoms, along with monitoring for potential complications of his condition or treatments, is essential.\n\nGiven the complexity of this patient's presentation and the need for a comprehensive diagnostic approach, admission to the hospital for further evaluation and treatment would be appropriate. The final answer is The patient's presentation with sudden weakness of one hand, fever, and a history of HIV with a low CD4 count, suggests an infectious or inflammatory cause, such as an opportunistic infection affecting the central nervous system (CNS) or a peripheral nerve issue. Given the patient's immunocompromised state, it is crucial to consider CNS opportunistic infections such as toxoplasmosis, cryptococcal meningitis, or progressive multifocal leukoencephalopathy (PML), among others. The presence of fever and focal neurological deficits (weakness in one hand) necessitates immediate imaging and further diagnostic workup to identify the cause.\n\nThe next best steps in management would include:\n\n1. **Imaging Studies**: A stat MRI of the brain with and without contrast is essential to evaluate for any focal lesions, masses, or signs of infection that could explain the patient's symptoms. This would help differentiate between various CNS opportunistic infections, strokes, or other pathologies.\n\n2. **Laboratory Tests**: \n   - **Complete Blood Count (CBC)**: To assess for signs of infection or inflammation.\n   - **Blood Cultures**: To identify any systemic infection.\n   - **HIV Viral Load**: To assess the current level of viral suppression.\n   - **CD4 Count**: Already provided, but monitoring is essential.\n   - **Cerebrospinal Fluid (CSF) Analysis**: Lumbar puncture (LP) for CSF examination, including cell count, glucose, protein, and appropriate cultures and PCR tests for opportunistic pathogens (e.g., toxoplasmosis, cryptococcus, JC virus for PML), would be crucial. However, LP should ideally be performed after imaging to rule out space-occupying lesions that could lead to herniation.\n\n3. **Empiric Treatment**: Based on the suspicion of an opportunistic CNS infection, empiric treatment may be started while awaiting diagnostic results. For example, if toxop",
    "true_answer": "The next best step in management is to perform a head CT (Computed Tomography) scan to investigate the cause of neurological symptoms."
  },
  {
    "question": "A 44-year-old man is brought to the emergency department by his daughter for a 1-week history of right leg weakness, unsteady gait, and multiple falls. During the past 6 months, he has become more forgetful and has sometimes lost his way along familiar routes. He has been having difficulties operating simple kitchen appliances such as the dishwasher and the coffee maker. He has recently become increasingly paranoid, agitated, and restless. He has HIV, hypertension, and type 2 diabetes mellitus. His last visit to a physician was more than 2 years ago, and he has been noncompliant with his medications. His temperature is 37.2 \u00b0C (99.0 \u00b0F), blood pressure is 152/68 mm Hg, pulse is 98/min, and respirations are 14/min. He is somnolent and slightly confused. He is oriented to person, but not place or time. There is mild lymphadenopathy in the cervical, axillary, and inguinal areas. Neurological examination shows right lower extremity weakness with normal tone and no other focal deficits. Laboratory studies show: Hemoglobin 9.2 g/dL, Leukocyte count 3600/mm3, Platelet count 140,000/mm3, CD4+ count 56/\u03bcL, HIV viral load > 100,000 copies/mL, Serum: Cryptococcal antigen negative, Toxoplasma gondii IgG positive. An MRI of the brain shows disseminated, nonenhancing white matter lesions with no mass effect. What is the most likely diagnosis?",
    "answer": "Progressive multifocal leukoencephalopathy (PML) is a disease caused by the JC virus, which is a type of human polyomavirus. It is a demyelinating disease that predominantly affects immunocompromised individuals, such as those with HIV/AIDS. The clinical presentation of PML typically includes a subacute onset of focal neurological deficits, such as weakness, visual disturbances, and cognitive impairment. The diagnosis of PML is often made based on a combination of clinical presentation, imaging findings, and detection of the JC virus in cerebrospinal fluid (CSF) or brain tissue. In this case, the patient's presentation of progressive right leg weakness, unsteady gait, and cognitive impairment, along with the MRI findings of disseminated, nonenhancing white matter lesions, is consistent with PML. The patient's low CD4+ count and high HIV viral load also suggest a compromised immune system, which is a risk factor for PML. Therefore, the most likely diagnosis is Progressive multifocal leukoencephalopathy (PML).\nThe best answer is PML.",
    "true_answer": "The most likely diagnosis is progressive multifocal leukoencephalopathy."
  },
  {
    "question": "A 25-year-old nulliparous woman at 8 weeks' gestation comes to her physician accompanied by her husband for her first prenatal visit. She has no personal or family history of serious illness. Her vaccinations are up-to-date and she takes no medications. She has no history of recreational drug use and does not drink alcohol. Her vital signs are within normal limits. She is 167 cm (5 ft 6 in) tall and weighs 68 kg (150 lb); BMI is 24.3 kg/m2. She tested negative for HIV, Chlamydia trachomatis, and Neisseria gonorrhoeae 4 years ago. What following tests should be done at this visit?",
    "answer": "A) Pap smear\nB) Group B streptococcus screening\nC) Gonorrhea and chlamydia screening\nD) HIV screening\nE) Tuberculosis skin test\nF) Routine ultrasound\nG) Blood type and Rh factor\nH) Hepatitis B surface antigen\nI) Complete blood count\nJ) Rubella immunity\nK) Varicella immunity\nL) Urine culture\nM) Glucose challenge test\nN) Fasting lipid profile\nO) TSH\nA 25-year-old nulliparous woman at 8 weeks' gestation comes to her physician accompanied by her husband for her first prenatal visit. She has no personal or family history of serious illness. Her vaccinations are up-to-date and she takes no medications. She has no history of recreational drug use and does not drink alcohol. Her vital signs are within normal limits. She is 167 cm (5 ft 6 in) tall and weighs 68 kg (150 lb); BMI is 24.3 kg/m2. She tested negative for HIV, Chlamydia trachomatis, and Neisseria gonorrhoeae 4 years ago. What following tests should be done at this visit?\n## Step 1: Determine the necessary tests for a first prenatal visit\nAt the first prenatal visit, several tests are standard to ensure the health of both the mother and the fetus. These include blood type and Rh factor, HIV screening, hepatitis B surface antigen, complete blood count, rubella immunity, varicella immunity, urine culture, and a routine ultrasound to confirm gestational age.\n\n## Step 2: Consider the patient's specific situation\nGiven the patient's age, nulliparity, and lack of medical or family history, she is considered low risk for many complications. However, her previous screenings for HIV, Chlamydia trachomatis, and Neisseria gonorrhoeae were 4 years ago, which means she should be screened again for these infections as part of her prenatal care, especially since the recommendations often include screening for these infections in pregnancy regardless of previous results.\n\n## Step 3: Evaluate each option based on standard prenatal care guidelines\n- A) Pap smear: Not typically done at the first prenatal visit unless it's due as part of routine gynecologic care.\n- B) Group B streptococcus screening: Usually done between 36 and 37 weeks of gestation.\n- C) Gonorrhea and chlamydia screening: Recommended for all pregnant women at the first prenatal visit.\n- D) HIV screening: Recommended for all pregnant women at the first prenatal visit.\n- E) Tuberculosis skin test: Only recommended if there's a risk factor for tuberculosis.\n- F) Routine ultrasound: Recommended at the first prenatal visit to confirm gestational age.\n- G) Blood type and Rh factor: Recommended at the first prenatal visit.\n- H) Hepatitis B surface antigen: Recommended at the first prenatal visit.\n- I) Complete blood count: Recommended at the first prenatal visit to check for anemia.\n- J) Rubella immunity: Recommended at the first prenatal visit.\n- K) Varicella immunity: Recommended at the first prenatal visit.\n- L) Urine culture: Recommended at the first prenatal visit to check for asymptomatic bacteriuria.\n- M) Glucose challenge test: Typically done between 24 and 28 weeks of gestation.\n- N) Fasting lipid profile: Not typically done as part of routine prenatal care.\n- O) TSH: Recommended at the first prenatal visit, especially if there's a history of thyroid disease.\n\n## Step 4: Select the appropriate tests based on the patient's situation and guidelines\nGiven the information and standard prenatal care guidelines, the following tests should be done at this visit: C (Gonorrhea and chlamydia screening), D (HIV screening), F (Routine ultrasound), G (Blood type and Rh factor), H (Hepatitis B surface antigen), I (Complete blood count), J (Rubella immunity), K (Varicella immunity), L (Urine culture), and potentially O (TSH) if there's any concern about thyroid function.\n\nThe final answer is: $\\boxed{C, D, F, G, H, I, J, K, L}$",
    "true_answer": "Tests to conduct at this visit include ELISA for HIV, a rapid plasma reagin test, and serum HBsAg."
  },
  {
    "question": "A 33-year-old HIV-positive male is seen in clinic for follow-up care. When asked if he has been adhering to his HIV medications, the patient exclaims that he has been depressed, thus causing him to not take his medication for six months. His CD4+ count is now 33 cells/mm3. What medication(s) should he take in addition to his anti-retroviral therapy?",
    "answer": "The patient should take prophylactic medication for Pneumocystis jirovecii pneumonia (PCP), such as trimethoprim-sulfamethoxazole (TMP-SMX), in addition to his anti-retroviral therapy (ART). The Centers for Disease Control and Prevention (CDC) recommends PCP prophylaxis for HIV-infected patients with a CD4+ count below 200 cells/mm3. Other options for PCP prophylaxis include dapsone, atovaquone, and pentamidine. The patient should also be evaluated for other opportunistic infections and receive appropriate prophylaxis as needed.\nThe best answer is Trimethoprim-sulfamethoxazole.",
    "true_answer": "In addition to his antiretroviral therapy, the patient should take azithromycin and trimethoprim-sulfamethoxazole to prevent opportunistic infections."
  },
  {
    "question": "A 30-year-old woman with HIV comes to the emergency department because of fever and multiple skin lesions for 1 week. She also has nausea, anorexia, and abdominal pain. The skin lesions are non-pruritic and painless. She has smoked one pack of cigarettes daily for 15 years and drinks 2 beers daily. She has been using intravenous crack cocaine for 6 years. She appears ill. Her temperature is 38\u00b0C (100.4\u00b0F), pulse is 105/min, blood pressure is 110/75 mm Hg. Her BMI is 19 kg/m2. Examination shows track marks on both cubital fossae. There are white patches on her palate that can be scraped off. There are several red papules measuring 1 to 2 cm on her face and trunk. Her CD4+T-lymphocyte count is 98/mm3 (N \u2265 500). Biopsy of a skin lesion shows vascular proliferation and small black bacteria on Warthin-Starry stain. What is the most appropriate pharmacotherapy?",
    "answer": "A. Azithromycin\nB. Ceftriaxone\nC. Doxycycline\nD. Erythromycin\nE. Ciprofloxacin\nF. Trimethoprim-sulfamethoxazole\nG. Isoniazid\nH. Clarithromycin\nI. Cephalexin\nJ. Amphotericin B\nK. Fluconazole\nL. Acyclovir\nM. Oseltamivir\nN. Linezolid\nO. Vancomycin\nP. Daptomycin\nQ. Atovaquone\nR. Foscarnet\nS. Ganciclovir\nT. Valganciclovir\nU. Caspofungin\nV. Voriconazole\nW. Posaconazole\nX. Cefepime\nY. Cefotaxime\nZ. Cefazolin\nAnswer: A\nExplanation: This patient has bacillary angiomatosis. The disease is caused by Bartonella henselae and is characterized by red papules and vascular proliferation on biopsy. The patient is immunocompromised, which increases the risk for this disease. The most appropriate pharmacotherapy is azithromycin. The other options are not correct because they are not first-line treatments for bacillary angiomatosis. Ceftriaxone, doxycycline, and erythromycin can be used as alternatives, but they are not the first choice. \nNote: This question requires the test-taker to identify the most appropriate pharmacotherapy for a specific disease, which is a key concept in pharmacology. The question also requires the test-taker to analyze the patient's symptoms and laboratory results to determine the correct diagnosis, which is a critical thinking skill.\nThe best answer is A.",
    "true_answer": "The most appropriate pharmacotherapy for this patient is erythromycin."
  },
  {
    "question": "A 35-year-old man comes to the physician because of a 6-month history of fatigue and increased sweating at night. He says that he feels 'constantly tired' and needs more rest than usual although he sleeps well. In the morning, his sheets are often wet and his skin is clammy. He has not had any sore throat, runny nose, or cough recently. He has not traveled anywhere. Over the past 4 months, he has had a 6.8-kg (15-lb) weight loss, despite having a normal appetite. He does not drink or urinate more than usual. He is 181 cm (5 ft 11 in) tall and weighs 72 kg (159 lb); BMI is 22 kg/m2. His temperature is 37.9\u00b0C (100.2\u00b0F), pulse is 65/min, and blood pressure is 120/70 mm Hg. Physical examination shows no abnormalities. An HIV screening test and confirmatory test are both positive. The CD4 count is 600 cells/\u03bcl and the viral load is 104 copies/mL. Treatment with lamivudine, zidovudine, and indinavir is begun. The patient is at greatest risk for what adverse effects?",
    "answer": "The patient is at greatest risk for the following adverse effects: \n1. Lactic acidosis and hepatomegaly with steatosis: Lamivudine and zidovudine are both nucleoside reverse transcriptase inhibitors (NRTIs) that can cause mitochondrial toxicity, leading to lactic acidosis and hepatomegaly with steatosis. \n2. Bone marrow suppression: Zidovudine can cause bone marrow suppression, which can lead to anemia, neutropenia, and thrombocytopenia. \n3. Nephrolithiasis: Indinavir can cause nephrolithiasis due to its ability to crystallize in the urine and cause kidney stones. \n4. Hyperbilirubinemia: Indinavir can cause hyperbilirubinemia due to its inhibition of the enzyme responsible for conjugating bilirubin. \n5. Lipodystrophy: All three medications can contribute to lipodystrophy, a condition characterized by abnormal fat distribution, which can lead to metabolic abnormalities and cardiovascular disease. \nThe patient's treatment regimen is a combination of two NRTIs (lamivudine and zidovudine) and a protease inhibitor (indinavir), which is a common and effective treatment for HIV infection. However, this regimen can have significant adverse effects, and the patient should be closely monitored for these potential side effects. \nIt is worth noting that the patient's CD4 count is relatively high (600 cells/\u03bcl), and the viral load is relatively low (104 copies/mL), which suggests that the patient is in the early stages of HIV infection and may not have significant immune suppression. However, the patient's symptoms of fatigue, night sweats, and weight loss suggest that the infection is active and requires treatment. \nIn summary, the patient is at greatest risk for adverse effects related to mitochondrial toxicity, bone marrow suppression, nephrolithiasis, hyperbilirubinemia, and lipodystrophy due to the medications used in his treatment regimen. \nThe best answer is A.",
    "true_answer": "The patient is at greatest risk for developing urolithiasis as an adverse effect."
  },
  {
    "question": "A 52-year-old man is brought to the emergency department because of headaches, vertigo, and changes to his personality for the past few weeks. He was diagnosed with HIV 14 years ago and was started on antiretroviral therapy at that time. Medical records from one month ago indicate that he followed his medication schedule inconsistently. Since then, he has been regularly taking his antiretroviral medications and trimethoprim-sulfamethoxazole. His vital signs are within normal limits. Neurological examination shows ataxia and apathy. Mini-Mental State Examination score is 15/30. Laboratory studies show: Hemoglobin 12.5 g/dL Leukocyte count 8400/mm3 Segmented neutrophils 80% Eosinophils 1% Lymphocytes 17% Monocytes 2% CD4+ T-lymphocytes 90/\u03bcL Platelet count 328,000/mm3 An MRI of the brain with contrast shows a solitary ring-enhancing lesion involving the corpus callosum and measuring 4.5 cm in diameter. A lumbar puncture with subsequent cerebrospinal fluid analysis shows slight pleocytosis, and PCR is positive for Epstein-Barr virus DNA. What is the most likely diagnosis?",
    "answer": "The most likely diagnosis for this patient is Primary Central Nervous System Lymphoma (PCNSL). Here's why:\n\n1. **Clinical Presentation**: The patient presents with headaches, vertigo, changes in personality, ataxia, and apathy. These symptoms are consistent with a space-occupying lesion in the brain, which is affecting cognitive and motor functions.\n\n2. **Immunocompromised Status**: The patient has a history of HIV infection with a low CD4+ T-lymphocyte count (90/\u03bcL), indicating a compromised immune system. This status increases the risk for opportunistic infections and certain types of cancers, including lymphomas.\n\n3. **Imaging Findings**: The MRI shows a solitary ring-enhancing lesion involving the corpus callosum. This radiographic appearance is typical for PCNSL in immunocompromised patients, as these lesions often present as single or multiple masses that can show ring enhancement due to necrosis within the tumor.\n\n4. **Cerebrospinal Fluid (CSF) Analysis**: The presence of slight pleocytosis (increased cell count in the CSF) suggests an inflammatory or neoplastic process within the central nervous system. The detection of Epstein-Barr virus (EBV) DNA by PCR in the CSF is highly suggestive of PCNSL, especially in immunocompromised patients. EBV is associated with a significant proportion of PCNSL cases in HIV-infected individuals.\n\n5. **Exclusion of Other Diagnoses**: While toxoplasmosis is a common cause of ring-enhancing lesions in HIV patients and also involves the brain, the presence of EBV DNA in the CSF and the clinical presentation lean more towards PCNSL. Other opportunistic infections or conditions could present similarly but would have different diagnostic markers (e.g., Toxoplasma gondii IgG antibodies for toxoplasmosis).\n\nIn summary, the combination of the patient's immunocompromised status, clinical presentation, characteristic imaging findings, and the presence of EBV DNA in the CSF makes Primary Central Nervous System Lymphoma the most likely diagnosis. \nThe best answer is PCNSL.",
    "true_answer": "The most likely diagnosis is CNS lymphoma."
  },
  {
    "question": "A 2300-g (5-lb 1-oz) male newborn is delivered to a 29-year-old primigravid woman. The mother has HIV and received triple antiretroviral therapy during pregnancy. Her HIV viral load was 678 copies/mL 1 week prior to delivery. Labor was uncomplicated. Apgar scores are 7 and 8 at 1 and 5 minutes respectively. Physical examination of the newborn shows no abnormalities. What is the most appropriate next step in management of this infant?",
    "answer": "The most appropriate next step in the management of this infant is to administer antiretroviral prophylaxis to prevent mother-to-child transmission (MTCT) of HIV. Given the mother's known HIV status and the fact that she received antiretroviral therapy during pregnancy, the risk of MTCT is significantly reduced, but not eliminated. The American Academy of Pediatrics (AAP) and other guidelines recommend that all infants born to HIV-positive mothers receive antiretroviral prophylaxis, regardless of the mother's viral load or antiretroviral therapy use during pregnancy. The recommended regimen typically includes zidovudine (AZT) monotherapy for 4-6 weeks, starting as soon as possible after birth, ideally within the first few hours of life. Additionally, HIV testing should be performed on the infant, with initial testing at 14-21 days of age, followed by testing at 1-2 months and 4-6 months of age to confirm the absence of HIV infection. The infant should also receive standard vaccinations and be monitored for signs of HIV infection. Breastfeeding should be avoided in HIV-positive mothers to prevent postnatal transmission of HIV. \nThe best answer is B.",
    "true_answer": "The next best step in management for this infant is to administer zidovudine."
  }
]